Journal of Cardiovascular Pharmacology

Journal Logo

Advanced Search

March 2023 - Volume 81 - Issue 3

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 75/143, Pharmacology & Pharmacy 162/279
  • 3.271

The Intestinal Flora Metabolite Trimethylamine Oxide Is Inextricably Linked to Coronary Heart Disease (Honghong Zhang, Lele Jing, Changlin Zhai, Qiannan Xiang, Hongen Tian, Huilin Hu). Atherosclerotic coronary heart disease is a common cardiovascular disease with high morbidity and mortality. In recent years, the incidence of coronary heart disease has gradually become younger, and biomarkers for predicting coronary heart disease have demonstrated-valuable clinical prospects. Several studies have established an association between coronary heart disease and intestinal flora metabolites, including trimethylamine oxide (TMAO), which has attracted widespread attention from researchers. Investigations have also shown that plasma levels of TMAO and its precursors can predict cardiovascular risk in humans; however, TMAO's mechanism of action in causing coronary heart disease is not fully understood. This review examines TMAO's generation, the mechanism through which it causes coronary heart disease, and the approaches used to treat TMAO-caused coronary heart disease to possible avenues for future research on coronary heart disease and find new concepts for the treatment of the condition.​




 ​

Current Issue Highlights

​2021 Twitter logo - blue.pnglinkedinlogo.png​

The editors of JCVP are calling for the submission of review articles dealing with all aspects of ER signaling in the heart, including the cGAS–cGAMP–STING pathway, mitochondria associated membranes, unfolded protein response (UPR), inflammasome activation, and ER stress. Articles with a therapeutic and disease-based perspective are welcomed. All articles will undergo peer review and appear in a regular issue in early 2023. Please contact the editorial office for additional information and prior approval for submission. ​​

The Journal of Cardiovascular Pharmacology announces an open call for a new review series dealing with the rapidly developing topic of RNA-based therapies. Reviews should focus on treating cardiovascular diseases or disorders, such as myocardial infarction, cardiac hypertrophy, cardiomyopathies, arrhythmias, valvular heart disease, aortic aneurysms, atherosclerosis and dysliidemia, and cerebrovascular disease. Various approaches, such as RNA aptamers, long non-coding RNAs, microRNAs, antisense nucleotides, and novel delivery strategies are included. The series is scheduled to appear early 2023. Please contact the editorial office for additional information and prior approval for submission.​​

View More Featured Jobs
Powered by: